GZMH gene
Radiance Biopharma Secures $1.2 Billion Deal for Novel ROR1-Targeted Antibody-Drug Conjugate from CSPC
Radiance Biopharma, CSPC Pharmaceutical, ROR1, antibody-drug conjugate (ADC), oncology, licensing deal, biopharmaceutical partnership
AstraZeneca Invests $2 Billion in CSPC’s Lipid-Lowering Therapy
AstraZeneca, CSPC Pharmaceutical Group, lipid-lowering therapy, Lp(a) disruptor, cardiovascular disease, pharmaceutical investment